Timothy Paul Heffernan

KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

This study identifies ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer by analyzing proteomic changes induced by KRAS inhibition and developing an antibody drug conjugate.

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer

This study identifies small molecule Kras inhibitors that synergize with anti-CTLA4 therapy to reprogram Tregs and enhance immunotherapy efficacy in PDAC.

CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma

This study investigates how CDK8 remodels the tumor microenvironment to resist KRASG12D inhibition in PDAC, showing that targeting CDK8 can overcome resistance and improve survival.

WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer

This study shows that disrupting the WRAD core in pancreatic cancer leads to DNA replication errors, immune response activation, and improved response to immune checkpoint inhibitors.